Top Markets
#1 Seeker Seeker +131.55%
#2 MowCat MowCat +108.83%
#3 Helium Helium +94.89%
#4 AI XOVIA AI XOVIA +91.25%
#5 Pons Pons +48.34%
#6 UnifAI Network UnifAI Network +33.34%
#7 Zora Zora +25.69%
#8 Bounce Bounce +25.32%
#9 Zylo Ecosystem Zylo Ecosystem +21.51%
#10 pipedog pipedog +18.86%
Coin of the day
Seeker Seeker
설정
언어
한국어
통화
USD
테마
BridgeBio Oncology Therapeutics Inc. BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics Inc.

BBOT
주식 순위 #11444
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical... BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
주가
$8.74
마지막 동기화: 2026-08-28
시가총액
$699.74M
변동 (1일)
-4.85%
변동 (1년)
-2.29%
국가
US
거래 BridgeBio Oncology Therapeutics Inc. (BBOT)

카테고리

Healthcare
BridgeBio Oncology Therapeutics Inc. (BBOT)의 매출
Aug 2026 기준 매출 TTM: 0
BridgeBio Oncology Therapeutics Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 0 대비 동일입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
BridgeBio Oncology Therapeutics Inc.의 수익 기록 (2026 ~ 2026)
매년 말 매출
연도 매출 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH